New Type of Interferon Shows Fewer Side Effects and Better Treatment Rate
April 18, 2011
Promising early results from the EMERGE study of the new drug peg-interferon lambda show that people tolerate it better than the current peg-interferon alpha. The lambda version also appears to suppress hepatitis C (HCV) to undetectable levels in more people than the alpha drug.
As one of the two drugs used in current standard treatment, peg-interferon (pIFN) alpha can cause troublesome side effects, including severe flu-like symptoms such as muscle aches and pains, nausea, fever, headache, tiredness and dry skin, as well as anxiety and depression. This newer version appears to cause far fewer side effects, and may even offer people a better option to standard treatment.View Full Article
Visit Project Inform's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)